<DOC>
	<DOCNO>NCT00970411</DOCNO>
	<brief_summary>The purpose study assess safety tolerability KRN951 administer patient solid tumor . In single dose period , patient cohort receive one oral dose KRN951 first day , follow 6-day rest period treatment receive . After , patient cohort receive one oral dose KRN951 daily 21-day treatment period , follow 7-day rest period treatment receive . Treatment continue absence disease progression unacceptable adverse event .</brief_summary>
	<brief_title>Study KRN951 Patients With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Signed write informed consent Solid tumor unresponsive , untreatable standard therapy â‰¥ threemonth life expectancy Eastern Cooperative Oncology Group Performance Status score 0 , 1 2 Hematologic abnormality Myocardial infarction clinically symptomatic leave ventricular failure Active hypertension controllable hypertension 3 antihypertensive medication Symptomatic CNS metastasis Unhealed wound Active infection Hepatic renal functional disorder Any HBs antigen , HCV antibody HIV antibody positivity Prior use chemotherapy , radiotherapy , immunotherapy surgery within four week previous first dose study drug Pregnant lactate woman Women childbearing potential fertile men , unless willing use adequate contraceptive protection</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>